TY - JOUR
T1 - The severe impairment battery
T2 - Concurrent validity and the assessment of longitudinal change in Alzheimer's disease
AU - Schmitt, Frederick A.
AU - Ashford, Wesson
AU - Ernesto, Christopher
AU - Saxton, Judith
AU - Schneider, Lon S.
AU - Clark, Christopher M.
AU - Ferris, Steven H.
AU - Mackell, Joan A.
AU - Schafer, Kimberly
AU - Thal, Leon J.
PY - 1997
Y1 - 1997
N2 - Measurement of cognitive dysfunction in the early stages of Alzheimer's disease (AD) has been well studied and there are many objective tests in use for this purpose. However, with the exception of clinical rating scales, such as the Clinical Dementia Rating Scale, Global Deterioration Scale, and Functional Assessment Staging, there are few objective measures of cognition in the more advanced stages of AD. Given a renewed interest in potential AD therapies, objective measures of mental functioning are needed to adequately assess change in more advanced AD patients. As part of an effort by the NIA-Alzheimer's Disease Cooperative Study to evaluate new measures of efficacy for their utility in treatment studies, the Severe Impairment Battery (SIB) was examined in a 1-year evaluation of change across a wide range of AD severity. The data suggest that the SIB is a reliable and valid measure of progression, particularly in persons with moderate to severe AD. The SIB may therefore be a useful outcome measure in clinical trials that include patients with more advanced stages of AD.
AB - Measurement of cognitive dysfunction in the early stages of Alzheimer's disease (AD) has been well studied and there are many objective tests in use for this purpose. However, with the exception of clinical rating scales, such as the Clinical Dementia Rating Scale, Global Deterioration Scale, and Functional Assessment Staging, there are few objective measures of cognition in the more advanced stages of AD. Given a renewed interest in potential AD therapies, objective measures of mental functioning are needed to adequately assess change in more advanced AD patients. As part of an effort by the NIA-Alzheimer's Disease Cooperative Study to evaluate new measures of efficacy for their utility in treatment studies, the Severe Impairment Battery (SIB) was examined in a 1-year evaluation of change across a wide range of AD severity. The data suggest that the SIB is a reliable and valid measure of progression, particularly in persons with moderate to severe AD. The SIB may therefore be a useful outcome measure in clinical trials that include patients with more advanced stages of AD.
KW - Alzheimer's disease
KW - Alzheimer's disease cooperative study
KW - Clinical ratings
KW - Cognition
KW - Longitudinal measurement
KW - Severe impairment
UR - http://www.scopus.com/inward/record.url?scp=0030801505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030801505&partnerID=8YFLogxK
M3 - Article
C2 - 9236953
AN - SCOPUS:0030801505
SN - 0893-0341
VL - 11
SP - S51-S56
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
IS - SUPPL. 2
ER -
